The binding of [3H]chlorambucil to nuclear proteins of the Yoshida ascites sarcoma.
The binding of [3H]chlorambucil to nuclear proteins, extracted from Yoshida ascites sarcoma cells at 6 h and 24 h after administration of 3H-labelled drug to tumour-bearing animals, has been examined. Both covalent and non-covalent binding was detected. Considerably more drug was found associated with the proteins isolated from the tumour sensitive to the effects of the drug compared with similar proteins isolated from the tumour with an acquired resistance to the effects of alkylating agents. The two-fold difference in binding to total cell protein is attributed to a higher intranuclear protein binding in sensitive cells. In particular the soluble nuclear sap fraction from sensitive cells bound at least five times as much drug as the corresponding fraction from resistant cells. Low levels of binding to histones were demonstrated compared with that to the non-histone chromatin proteins. Binding to the nuclear sap and non-histone chromatin proteins was principally to high molecular weight protein species; these did not appear to represent aggregation products as scans of stained polyacrylamide gels of the extracted protein fractions were unaltered by the treatment of tumour-bearing animals with chlorambucil. Binding to the nuclear proteins from sensitive cells tended to persist over a 24-h period, whereas it was considerably reduced in resistant cells.
D000818:Animals; D002467:Cell Nucleus / Q000378:metabolism; D002699:Chlorambucil / Q000378:metabolism*; D002843:Chromatin / Q000378:metabolism; D004351:Drug Resistance; D005260:Female; D009698:Nucleoproteins / Q000378:metabolism*; D011485:Protein Binding; D051381:Rats; D011955:Receptors, Drug; D012517:Sarcoma, Yoshida / Q000378:metabolism*
D002843:Chromatin; D009698:Nucleoproteins; D011955:Receptors, Drug; D002699:Chlorambucil